Targeting interleukin-22 for cancer therapy.
Hum Vaccin Immunother
; 14(8): 2012-2015, 2018.
Article
em En
| MEDLINE
| ID: mdl-29617184
ABSTRACT
Interleukin-22 (IL-22) is a member of IL-10 family of cytokines. IL-22 induces proliferative and anti-apoptotic signaling pathways and production of anti-microbial molecules that enhance tissue regeneration and host defense. IL-22 has also been identified as a cancer-promoting cytokine since deregulation of the IL-22-IL-22R1 system is linked to different cancer entities including lung, breast, gastric, pancreatic and colon cancers. T cells and innate lymphoid cells are the main cellular sources of IL-22. Expression of its specific receptor IL-22R1 is restricted to the non-hematopoietic cells which makes the IL-22-IL-22R1 pathway an attractive target for anti-cancer therapy. For development of such therapies, a better understanding of IL-22 regulation in the tumor microenvironment is needed. We could recently decipher how cancer cells promote IL-22 production by memory T cells via induction of IL-1. Here we will discuss how this knowledge might contribute to developing therapies disregulating the IL-22 pathway for cancer immunotherapy.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Interleucinas
/
Receptores de Interleucina
/
Microambiente Tumoral
/
Antineoplásicos Imunológicos
/
Neoplasias
Limite:
Humans
Idioma:
En
Ano de publicação:
2018
Tipo de documento:
Article